2. Academic Validation
  3. Therapeutic Targeting of the IRF9/RTN4/RHOA/ROCK Pathway via RVG29-Modified PLGA Nanoparticles and rTMS for Neural and Vascular Regeneration Post-Cerebral Infarction

Therapeutic Targeting of the IRF9/RTN4/RHOA/ROCK Pathway via RVG29-Modified PLGA Nanoparticles and rTMS for Neural and Vascular Regeneration Post-Cerebral Infarction

  • Adv Healthc Mater. 2025 Sep 18:e01846. doi: 10.1002/adhm.202501846.
Fangfang Zhang 1 2,  Weijin Shen 3,  Siting Zhong 4 5,  Kai Wen 6,  Hongxing Wang 7 8
Affiliations

Affiliations

  • 1 Department of Anesthesiology, Xiangya Hospital, Central South University, Changsha, 410000, China.
  • 2 National Clinical Research Center for Geriatric Disorders, Xiangya Hospital Central South University, Changsha, Hunan, 410000, China.
  • 3 Department of Rehabilitation, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, China.
  • 4 Department of Rehabilitation, Xiangya Hospital, Central South University, Jiangxi. (National Regional Center for Neurological Diseases), Nanchang, Jiangxi, 330038, China.
  • 5 Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, 330038, China.
  • 6 Department of Rehabilitation, Xiangya Changde Hospital, Changde, 415000, China.
  • 7 Department of Rehabilitation, Chongqing University Three Gorges Hospital，School of Medicine，Chongqing University, Chongqing, 404100, China.
  • 8 Xinjiang Key Laboratory of Neurological Disorder Research, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, China.
PMID: 40968528 DOI: 10.1002/adhm.202501846
Abstract

Cerebral infarction, a leading cerebrovascular disease, often results in severe neurological impairments and high mortality. This study investigates a novel therapeutic approach involving small interfering RNA targeting Interferon Regulatory Factor 9 (si-IRF9) delivered by RVG29-functionalized poly(lactic-co-glycolic acid) nanoparticles (NPs) (RVG29-PNPs@si-IRF9), in combination with high-frequency repetitive transcranial magnetic stimulation (rTMS), in promoting post-stroke regeneration. Using a middle cerebral artery occlusion rat model and an in vitro oxygen-glucose deprivation/reoxygenation system, the regenerative efficacy of this combinatory therapy is evaluated on both neural and vascular recovery. Mechanistically, our results identify the IRF9/Reticulon 4 (RTN4)/Ras homolog family member A (RHOA)/Rho-associated coiled-coil containing protein kinase (ROCK) pathway as a key mediator, which is effectively inhibited by RVG29-PNPs@si-IRF9. This inhibition enhances neurogenesis and angiogenesis, particularly when combined with rTMS. Moreover, the NP system demonstrates excellent biocompatibility and targeted delivery, highlighting its potential as a therapeutic platform for stroke rehabilitation. These findings provide a new perspective on integrating nanotechnology and neuromodulation to facilitate functional recovery after cerebral infarction.

Keywords

RVG29‐modified PLGA nanoparticles; cerebral infarction; neural regeneration; si‐IRF9; transcranial magnetic stimulation; vascular regeneration.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z